Cross-sectional characteristics of pediatric-onset discoid lupus erythematosus: Results of a multicenter, retrospective cohort study.

BACKGROUND: The incidence of systemic lupus in children with discoid lupus is unknown. OBJECTIVE: This study assessed the baseline characteristics of patients with pediatric discoid lupus erythematosus (pDLE). METHODS: Medical records at 17 sites were reviewed for pediatric dermatology and rheumatology patients with discoid lupus erythematosus. The inclusion criteria were clinical and/or histopathologic diagnosis of discoid lupus erythematosus with an age at onset of <18 years. Baseline data were collected at the first documented visit. Outcomes included diagnosis of systemic lupus erythematosus (SLE) at the baseline visit using the 1997 American College of Rheumatology (primary) and the 2012 Systemic Lupus International Collaborating Clinics (secondary) criteria. RESULTS: Of the >1500 charts reviewed, 438 patients met the inclusion criteria. The cohort was predominantly female (72%) and racially/ethnically diverse. A diagnosis of SLE at the baseline visit (pDLE + SLE) was rendered in 162 (37%) patients using the American College of Rheumatology and in 181 (41%) patients using the Systemic Lupus International Collaborating Clinics criteria. Patients with pDLE + SLE were older at the time of rash onset (median, 12.9 vs 8.9 years; P < .001), with shorter time from discoid lupus erythematosus onset to diagnosis, compared with patients with pDLE-only (median, 2 vs 7 months; P < .001). Patients with pDLE + SLE were more likely to be female (P = .004), with generalized discoid lupus erythematosus and clinically aggressive disease, including end-organ involvement, positive serologies, and higher- titer levels of antinuclear antibodies (P < .001). LIMITATIONS: Retrospective study. CONCLUSION: A diagnosis of discoid lupus erythematosus in adolescence should prompt thorough screening for SLE.

Rowell syndrome complicated with macrophage activation syndrome in a child.

Rowell syndrome (RS) is a rare disease characterized by the association of systemic lupus erythematosus (SLE) or cutaneous lupus with lesions similar to erythema multiforme and the presence of autoantibodies including ANA, SSA, SSB, or rheumatoid factor. Due to the low incidence of this disease, the epidemiology of RS is not clear. So far there are 95 cases reported in the literature; of these, only seven cases are pediatric patients. Macrophage activation syndrome (MAS) is an increasingly recognized complication of SLE, although its true prevalence in childhood is still unknown. We describe a unique pediatric patient with RS who developed MAS.

Expanding the clinical features of autoinflammation and phospholipase Cγ2-associated antibody deficiency and immune dysregulation by description of a novel patient.

BACKGROUND: Autoinflammation and phospholipase Cγ2-associated antibody deficiency and immune dysregulation (APLAID) is an exceedingly rare monogenic autoinflammatory disease. To date, only five cases have been reported with four distinct pathogenic mutations. OBJECTIVES: We present a novel case of APLAID, corroborated by molecular analysis, with newly described clinical findings including central nervous system vasculitis (CNSV); and distinctive histopathological characteristics that may expand our knowledge of this rare disease's phenotype. METHODS: This is a case report presentation of a 3-year-old boy, seen at a reference paediatric hospital in Mexico. His parents authorized the use of his clinical information and photographs. RESULTS: A 3-day-old boy presented to the emergency department with a vesiculo-pustular rash that resolved within 1 week. Two months later, he developed widespread papules and pseudovesicles that evolved into infiltrated plaques. He also had periodical flares of conjunctivitis, diarrhoea and erythematous blistering acral plaques triggered by upper respiratory infections. By the age of 10 months, he experienced seizures and CNSV. Laboratory work-up showed mild neutropenia, decreased serum levels of immunoglobulins and B-cell lymphopenia. A skin biopsy revealed a dense, perivascular and interstitial histiocytic and granulomatous infiltrate, with palisading granulomas, and leucocytoclastic vasculitis with karyorrhexis. APLAID syndrome was confirmed by Sanger sequencing of PLCG2 gene [heterozygous genotype LRG_376t1:c.2543T>C or p.(Leu848Pro)]. CONCLUSIONS: Presence of CNSV has not been previously described in APLAID, however as the number of reported patients with APLAID is very small, it is possible that the overall spectrum of clinical manifestations has not been completely elucidated. The herein identified p.(Leu848Pro) variant was also documented in a Portuguese patient, suggesting that it could be a PLCG2 gene 'hot-spot'.

Development of Surface-Coated Polylactic Acid/Polyhydroxyalkanoate (PLA/PHA) Nanocomposites.

This work reports on the design and development of nanocomposites based on a polymeric matrix containing biodegradable Polylactic Acid (PLA) and Polyhydroxyalkanoate (PHA) coated with either Graphite NanoPlatelets (GNP) or silver nanoparticles (AgNP). Nanocomposites were obtained by mechanical mixing under mild conditions and low load contents (<0.10 wt %). This favours physical adhesion of the additives onto the polymer surface, while the polymeric bulk matrix remains unaffected. Nanocomposite characterisation was performed via optical and focused ion beam microscopy, proving these nanocomposites are selectively modified only on the surface, leaving bulk polymer unaffected. Processability of these materials was proven by the fabrication of samples via injection moulding and mechanical characterisation. Nanocomposites showed enhanced Young modulus and yield strength, as well as better thermal properties when compared with the unmodified polymer. In the case of AgNP coated nanocomposites, the surface was found to be optically active, as observed in the increase of the resolution of Raman spectra, acquired at least 10 times, proving these nanocomposites are promising candidates as surface enhanced Raman spectroscopy (SERS) substrates.

La recertificación que se avecina. ¿Miedo? Ninguno / Recertification is comming. Afraid? Not al all

No disponible

Subcutaneous immunoglobulin for the treatment of deep morphoea in a child.

Morphoea, also known as localized scleroderma, is a disorder characterized by excessive collagen deposition leading to thickening of the dermis and/or subcutaneous tissues. Intravenous IgG therapy has induced improvement in some fibrotic conditions. The primary indication for subcutaneous IgG (SCIG) is in primary immunodeficiency disorders as replacement therapy; however, recently there has been considerable interest in SCIG as an immunomodulatory agent. We report an 11-year-old girl with deep morphoea who was successfully treated with SCIG.

[Possible treatments for infantile spinal atrophy]. / Posibilidades de tratamiento en la atrofia espinal infantil.

The new treatments of spinal muscular atrophy (SMA) due by SMN1 gene deletions are reviewed. There are several ways to increase the protein SMN, its activity and persistence in the tissues. Neuroprotective drugs as olesoxime or riluzole, and drugs acting by epigenetic mechanisms, as histone deacetylase inhibitors, have shown positive effects in preclinical studies but no clear efficacy in clinical trials. They might give in the future added benefits when used associated to other genetic modifying drugs. The best improvements in murine models of SMA and in clinical trials have been reached with antisense oligonucleotides, drugs that modify the splicing of SMN2, and they are expected to get better in the near future. Nusinersen, a methoxi-ethyl phosphotioate antisense oligonucleotide has recently approved for treatment of patients with SMA type 1 after having proved its efficacy in clinical trial phase 3. The results of nusinersen are reviewed. New modifications of antisense oligonucleotides with better access to brain, spinal cord and peripheral tissues are on the way. There are data of the efficacy of the genetic therapy with SMN1 gene through adenoassociated virus, now in phase 1 trial. A constant feature of these new treatments is that the earlier the treatment, the best are the results, and they are even better in presymptomatic stage. The general standards of care, particularly nutrition and respiratory management are needed in order to reach optimal results with the new therapies.

TITLE: Posibilidades de tratamiento en la atrofia espinal infantil.Se revisan los nuevos tratamientos de la atrofia muscular espinal (AME) producida por delecion del gen SMN1. Se describen las diferentes posibilidades de incrementar la proteina SMN, de su actividad y persistencia en el organismo. Farmacos neuroprotectores, como olesoxime y riluzol, y farmacos que actuan epigeneticamente, como inhibidores de histona deacetilasa, han mostrado cierto efecto positivo en fases preclinicas pero no han conseguido eficacia en los ensayos clinicos. Podrian proporcionar en un futuro un beneficio añadidos a otros farmacos modificadores geneticos. Los mayores cambios en estudios de modelos del raton SMA y en fases clinicas se han encontrado con oligonucleotidos antisentido que modifican el splicing del gen SMN2, y se espera que mejoren en el futuro proximo. Recientemente se ha aprobado el nusinersen, un metoxietilo fosforotioato-oligonucleotido antisentido, para uso en pacientes con AME de tipo I una vez demostrada su eficacia en pacientes en el ensayo en fase 3. Se revisan los resultados de este farmaco. Estan en marcha modificaciones de oligonucleotidos antisentido que amplien la liberacion en el sistema nervioso y en tejidos perifericos. Hay datos que sugieren eficacia de la terapia genica introduciendo el gen SMN1 mediante virus adenoasociados, actualmente en fase clinica 1. Una constante en estos nuevos tratamientos es que los resultados se optimizan en las etapas precoces de la enfermedad y, mejor aun, en estadio presintomatico. Se subraya la importancia de los cuidados generales optimos, especialmente nutricionales y respiratorios, para conseguir los mejores resultados con las nuevas terapias.

Analysis of genetic polymorphism of the HLA-B and HLA-DR loci in patients with dermatophytic onychomycosis and in their first-degree relatives.

Onychomycosis is known to have predisposing factors and a high prevalence within families that cannot be explained by within-family transmission. We determined the frequency of HLA-B and HLA-DR haplotypes in 25 families of Mexican patients with onychomycosis in order to define the role of the class II major histocompatibility complex (MHC) in genetic susceptibility to this infection. Seventy-eight subjects participated in the study, 47 with onychomycosis and 31 healthy individuals. The frequencies of the HLA-B and HLA-DR haplotypes were compared with those found in first-degree relatives without onychomycosis and in a historic control group of healthy individuals. The frequencies in the controls were similar to those of the healthy relatives of the patients. However, on comparison of the patients with historic controls, we detected a higher frequency of the HLA-DR8 haplotype (P=.03; odds ratio, 1.89; 95% confidence interval, 0.98-36). These findings suggest that there are polymorphisms in genes of the MHC that increase susceptibility to onychomycosis, particularly haplotype HLA-DR8.

[Analysis of genetic polymorphism of the HLA-B and HLA-DR loci in patients with dermatophytic onychomycosis and in their first-degree relatives]. / Análisis del polimorfismo genético de los loci HLA-B y HLA-DR en pacientes con onicomicosis dermatofítica y familiares en primer grado.

Onychomycosis is known to have predisposing factors and a high prevalence within families that cannot be explained by within-family transmission. We determined the frequency of HLA-B and HLA-DR haplotypes in 25 families of Mexican patients with onychomycosis in order to define the role of the class II major histocompatibility complex (MHC) in genetic susceptibility to this infection. Seventy-eight subjects participated in the study, 47 with onychomycosis and 31 healthy individuals. The frequencies of the HLA-B and HLA-DR haplotypes were compared with those found in first-degree relatives without onychomycosis and in a historic control group of healthy individuals. The frequencies in the controls were similar to those of the healthy relatives of the patients. However, on comparison of the patients with historic controls, we detected a higher frequency of the HLA-DR8 haplotype (P=.03; odds ratio, 1.89; 95% confidence interval, 0.98-36). These findings suggest that there are polymorphisms in genes of the MHC that increase susceptibility to onychomycosis, particularly haplotype HLA-DR8.

Zygomycosis in two hematologic cases.

Zygomycosis are invasive mould infections, rarely diagnosed in hematologic patients. Most of the cases published are in patients with prolonged neutropenia, along with other risk factors such as the use of prior broad-spectrum antibiotics (including new antifungal agents, such as voriconazole), diabetes mellitus (with or without ketoacidosis), malnutrition, iron overload (with or without the use of deferoxamine). These infections have poor prognosis due to the involvement of vital anatomic structures and late diagnosis. Until recent years, the treatment was based on high doses of amphotericin B plus surgical debridement. Here we present two patients with hematologic diseases (one with leukemia, the second with aplastic anemia) with an impaired immune system and the diagnosis of zygomycosis. The survival of one of them was mainly due to early diagnosis and surgical debridement; unfortunately the second was misdiagnosed as an extensive ecchymosis due to thrombocytopenia and died with CNS involvement.

¿Dónde queda reflejada la actividad enfermera desarrollada en los hospitales? / Where the nursing activity is reflected

Antecedentes y Objetivos: El Conjunto Mínimo Básico de Datos recoge información sobre la actividad hospitalaria. A través de la codificación se traduce la información del episodio clínico a un lenguaje numérico que clasifica cada paciente en un Grupo Relacionado por el Diagnóstico o GRD. En la codificación se emplea el Manual de la Clasificación Internacional de Enfermedades que recoge entre sus procedimientos algunas actividades propias del trabajo independiente que realiza enfermería. Nos propusimos describir el impacto del trabajo de enfermería en el Informe de Alta Médico, a través de los GRDs de episodios codificados, averiguar qué servicios registran mejor la actividad que realizan los profesionales de enfermería y analizar cómo influyen sobre el registro de actividades de enfermería variables como la entidad de afiliación y el motivo del alta. Material y Métodos: Procedimos a la extracción de las actividades de enfermería incluidas en el Manual de Codificación de la Clasificación Internacional de Enfermedades, encontrando 192 actividades propias de enfermería. Se empleó la Base de Datos de la actividad hospitalaria del año 2006 que se remite a la Consejería de Sanidad de la Comunidad Autónoma de Madrid, con 13.544 episodios codificados. Mediante el programa «Estación Clínica» de 3M®, se incluyeron las actividades de enfermería obtenidas, para conocer los GRDs en los que aparecía al menos una de las actividades de enfermería. Resultados y Discusión: Se analizaron y relacionaron los informes que describían al menos una actividad de enfermería con el total de episodios codificados. Se comparó la descripción de actividades de enfermería entre informes de servicios médicos y quirúrgicos. Se analizó la información en función de la entidad de afiliación y del motivo de alta. Se exponen las limitaciones del trabajo y se discuten los resultados obtenidos. Conclusiones: El Informe de Alta Médico es un documento que apenas refleja el trabajo del personal de enfermería en los hospitales. Los Servicios Médicos reflejan en mayor medida que los Servicios Quirúrgicos la actividad que realizan los profesionales de enfermería. La Clasificación Internacional de Enfermedades describe vagamente las actividades propias de enfermería, siendo necesarios estudios de contabilidad analítica que ponderen el peso que aportan las intervenciones de enfermería a los Grupos Relacionados por el Diagnóstico (AU)

Antecedents and Objectives: The Minimum Basic Data Set compiles information on hospital activity. Through its codification the clinical information is translated into a numerical language that classifies each patient into a Diagnosis-Related Group (DRG). This codification is based on the Manual of the International Classification of Diseases (ICD) that includes among its procedures some activities from the independent work carried out by nurses. Our purpose was to describe the impact of the nursing work on the medical discharge report through the DRG,s of codified clinical episodes, find out what departments have a better control of the work performed by the nursing professionals and analyze how variablessuch as health insurance entity and discharge reason influence the logging of nursing activities. Material and Methods: we proceeded to extract the nursing activities included in the Manual of the International Classification of Diseases, finding 192 nursing activities. The database of the hospital activity of 2006 that is sent to the Health Regional Ministry of the Autonomous Community of Madrid, including 13.544 codified episodes, was utilized. The nursing activities so obtained were included in the 3M“ software “Estación Clínica” in order to determine the DRG,s in which at least one nursing activity was identified. Results and Discussion: the reports that described at least one nursing activity were analyzed and correlated to the total of codified reports. The description of nursing activities in medical reports was compared in medical and surgical departments. The information was analyzed in accordance with the health insurance entity and the discharge reason. The limitations of this article are presented and the results discussed. Conclusions: the Medical Discharge Report is a document that hardly reflects the nursing personnel work in the hospitals. The medical departments tend to reflect to a greater extent than the surgical departments the activity of the nursing personnel. The International Classification of Diseases barely describes the nursing activities making necessary analytical accountancy methods in order to have a measure of the share of the nursing activities in the DRG,s (AU)

Critical assessment of the current guidelines for the management and treatment of morbidly obese patients.

An interdisciplinary panel of specialists met in Mallorca in the first European Symposium on Morbid Obesity entitled; "Morbid Obesity, an Interdisciplinary Approach". During the two and half days of the meeting, the participants discussed several aspects related to pathogenesis, evaluation, and treatment of morbid obesity. The expert panel included basic research scientists, dietitians and nutritionists, exercise physiologists, endocrinologists, psychiatrists, cardiologists, pneumonologists, anesthesiologists, and bariatric surgeons with expertise in the different weight loss surgeries. The symposium was sponsored by the Balearic Islands Health Department; however, this statement is an independent report of the panel and is not a policy statement of any of the sponsors or endorsers of the Symposium. The prevalence of morbid obesity, the most severe state of the disease, has become epidemic. The current recommendations for the therapy of the morbidly obese comes as a result of a National Institutes of Health (NIH) Consensus Conference held in 1991 and subsequently reviewed in 2004 by the American Society for Bariatric Surgery. This document reviews the work-up evaluation of the morbidly obese patient, the current status of the indications for bariatric surgery and which type of procedure should be recommended; it also brings up for discussion some important real-life clinical practice issues, which should be taken into consideration when evaluating and treating morbidly obese patients. Finally, it also goes through current scientific evidence supporting the potential effectiveness of medical therapy as treatment of patients with morbid obesity.